{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:25:04Z","timestamp":1787228704702,"version":"build-2736575974"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Circulating tumor DNA (ctDNA) is emerging as a minimally invasive biomarker for risk stratification and treatment-response assessment in lung cancer immunotherapy, but its routine use for treatment selection has not been established. This review critically evaluates evidence across neoadjuvant, adjuvant, consolidation after definitive chemoradiotherapy, and advanced\/metastatic settings, with emphasis on serial sampling and on the distinction among prognostic, response-associated, and predictive roles. Across disease stages, baseline or post-definitive-treatment ctDNA detectability consistently identifies patients at increased risk of recurrence or death and is therefore principally prognostic. Early on-treatment decline or clearance frequently precedes radiographic change and is associated with pathological response, progression-free survival, and overall survival, supporting ctDNA as a response-associated biomarker. By contrast, evidence that ctDNA identifies differential benefit from a specific immunotherapy remains limited, because most analyses are single-arm and\/or retrospective, formal treatment-by-biomarker interaction tests are uncommon, and prospective ctDNA-guided trials have not yet demonstrated clinical utility. Nevertheless, ctDNA dynamics provide a biologically and clinically coherent framework for future risk-adapted strategies, including enrichment of molecular residual disease-positive patients, early identification of resistance, and prospective testing of treatment escalation, de-escalation, or duration. Translation into routine care will require harmonized assays and sampling time points, improved sensitivity at low disease burden, control of clonal hematopoiesis, and randomized interventional validation. Thus, ctDNA currently functions mainly as a prognostic and response-associated biomarker in lung cancer immunotherapy, while its predictive, decision-defining role remains an important but investigational objective.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1911583","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:39:47Z","timestamp":1787225987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating tumor DNA in lung cancer immunotherapy: prognostic marker today, predictive tool tomorrow?"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Li","sequence":"first","affiliation":[{"name":"Cancer Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanyu","family":"Lu","sequence":"additional","affiliation":[{"name":"Cancer Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Song","sequence":"additional","affiliation":[{"name":"Cancer Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[{"name":"Cancer Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangliang","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Cancer Center, First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.671874","article-title":"The role of circulating tumor DNA in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.08.04","article-title":"Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not","volume":"7","author":"Heeke","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3649","article-title":"Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer","volume":"10","author":"Shi","year":"2021","journal-title":"Cancer Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70078","article-title":"Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients","volume":"13","author":"Fan","year":"2024","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108528","article-title":"ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach","volume":"203","author":"Rosenlund","year":"2025","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102791","article-title":"Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer","volume":"129","author":"Marinello","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.ccell.2024.08.013","article-title":"Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer","volume":"42","author":"Xu","year":"2024","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12916-022-02681-x","article-title":"Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer","volume":"20","author":"Shen","year":"2022","journal-title":"BMC Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.005","article-title":"Immunotherapy in resectable NSCLC: answering the question or questioning the answer","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2023.2220820","article-title":"The utility of ctDNA in lung cancer clinical research and practice: a systematic review and meta-analysis of clinical studies","volume":"41","author":"Sun","year":"2023","journal-title":"Cancer Invest"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.12.011","article-title":"LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer","volume":"20","author":"Swalduz","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.095","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02660","article-title":"Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1099304","article-title":"Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-01826-7","article-title":"The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer","volume":"16","author":"Passarella","year":"2025","journal-title":"Discov Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1563315","article-title":"Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients","volume":"15","author":"Lin","year":"2025","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00551-9","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.3390\/jcm14124127","article-title":"Systemic therapy for operable NSCLC: a review of the literature and discussion of future directions","volume":"14","author":"Mirsky","year":"2025","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2139\/ssrn.4908793","article-title":"Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial","volume":"9","author":"Zhong","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2632","article-title":"Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08834-1","article-title":"An ultrasensitive method for detection of cell-free RNA","volume":"641","author":"Nesselbush","year":"2025","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02445-1","article-title":"Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors","volume":"129","author":"Thompson","year":"2023","journal-title":"Br J Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-1341","article-title":"Early assessment of lung cancer immunotherapy response via circulating tumor DNA","volume":"24","author":"Goldberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2025.216767","article-title":"Liquid biopsy for cancer immunotherapy: biomarkers to predict and monitor response upon immune checkpoint blockade","volume":"539","author":"Son","year":"2025","journal-title":"Coord Chem Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.8080","article-title":"Integration of circulating tumor DNA and metabolic parameters on (18)F-fludeoxyglucose positron emission tomography for outcome prediction in unresectable locally advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2242","article-title":"Dynamics of sequence and structural cell-free DNA landscapes in small-cell lung cancer","volume":"29","author":"Sivapalan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101589","article-title":"Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer","volume":"27","author":"Visser","year":"2023","journal-title":"Transl Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.10.019","article-title":"Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence","volume":"151","author":"Gassa","year":"2021","journal-title":"Lung Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04794-z","article-title":"Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients","volume":"149","author":"Xi","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.10.013","article-title":"Brief report: methylation-based ctDNA serial monitoring correlates with immunotherapy response in NSCLC","volume":"26","author":"Hsiao","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06225-y","article-title":"Practical recommendations for using ctDNA in clinical decision making","volume":"619","author":"Cohen","year":"2023","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-3658","article-title":"Elevated ctDNA tumor fraction is associated with improved mutation detection but worse overall survival in advanced non-small cell lung cancer: A Lung-MAP study","volume":"31","author":"Mack","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.70054","article-title":"Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab","volume":"19","author":"Swanton","year":"2025","journal-title":"Mol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216569","article-title":"Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer","volume":"582","author":"Yang","year":"2024","journal-title":"Cancer Lett"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.05.021","article-title":"Quantitative and dynamic ctDNA as a biomarker of response and survival in patients with advanced lung squamous cell carcinoma receiving immunochemotherapy or chemotherapy alone","volume":"20","author":"Zhou","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B58","article-title":"Promising clinical application of ctDNA in evaluating immunotherapy efficacy","volume":"8","author":"Li","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1038\/s41467-024-47512-0","article-title":"Enhancing NSCLC recurrence prediction with PET\/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights","volume":"15","author":"Sujit","year":"2024","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0410","article-title":"Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer","volume":"27","author":"Parikh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa103","article-title":"Plasma or serum: Which is preferable for mutation detection in liquid biopsy","volume":"66","author":"Pittella-Silva","year":"2020","journal-title":"Clin Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00985-w","article-title":"Circulating tumour DNA in early stage and locally advanced NSCLC: Ready for clinical implementation","volume":"22","author":"Normanno","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.ccr-23-1469","article-title":"Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3044","article-title":"Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: A prospective multicenter cohort study (LUNGCA-1)","volume":"28","author":"Xia","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-106","article-title":"Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients","volume":"11","author":"Yue","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107855","article-title":"Immune checkpoint inhibition in early-stage non-small cell lung cancer","volume":"193","author":"Cuppens","year":"2024","journal-title":"Lung Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.07.002","article-title":"Clinical utility of tumor-na\u00efve presurgical circulating tumor DNA detection in early-stage NSCLC","volume":"19","author":"Hong","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","article-title":"Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf061","article-title":"Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study)","volume":"117","author":"Xia","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B71","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12943-021-01371-1","article-title":"Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer","volume":"20","author":"Nagasaka","year":"2021","journal-title":"Mol Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.annonc.2021.08.765","article-title":"Evaluation of cell-free DNA approaches for multi-cancer early detection","volume":"40","author":"Jamshidi","year":"2022","journal-title":"Cancer Cell"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05783-5","article-title":"The evolution of lung cancer and impact of subclonal selection in TRACERx","volume":"616","author":"Frankell","year":"2023","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/j.ccell.2026.05.002","article-title":"Subclonal immune evasion in non-small cell lung cancer","volume":"43","author":"Dijkstra","year":"2025","journal-title":"Cancer Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.376","article-title":"P03.03 MERMAID-1: A phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery","volume":"16","author":"Peters","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/s1556-0864(21)01935-3","article-title":"93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy","volume":"16","author":"Spigel","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.3390\/ijms23137222","article-title":"Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: Current evidence and ongoing trials","volume":"23","author":"de Scordilli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00432-024-06030-8","article-title":"Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacy","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041316-085721","article-title":"Circulating tumor DNA: Measurement and clinical utility","volume":"69","author":"Donaldson","year":"2018","journal-title":"Annu Rev Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","article-title":"Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients","volume":"41","author":"Pan","year":"2023","journal-title":"Cancer Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-022-01590-0","article-title":"The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients","volume":"21","author":"Yang","year":"2022","journal-title":"Mol Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.024","article-title":"Analysis of circulating tumor DNA predicts outcomes of short-course consolidation immunotherapy in unresectable stage III NSCLC","volume":"19","author":"Jun","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-025-02445-y","article-title":"Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients","volume":"10","author":"Yang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B86","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1038\/s41467-024-51316-7","article-title":"Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy","volume":"15","author":"Ding","year":"2024","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/diagnostics15070904","article-title":"The role of ctDNA for diagnosis and histological prediction in early stage non-small-cell lung cancer: A narrative review","volume":"15","author":"Sassorossi","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-25-0898","article-title":"Toward response-adaptive therapy in locally advanced NSCLC: Integrating ctDNA and radiomics for risk stratification","volume":"15","author":"Anagnostou","year":"2025","journal-title":"Cancer Discov"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01929","article-title":"Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent","volume":"40","author":"Pellini","year":"2022","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3291-8_11","article-title":"NGS-based tumor-informed analysis of circulating tumor DNA","volume":"2684","author":"Nordentoft","year":"2023","journal-title":"Methods Mol Biol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.1038\/s41467-021-27022-z","article-title":"Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC","volume":"12","author":"Qiu","year":"2021","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70316","article-title":"Predicting disease progression in inoperable localized NSCLC patients using ctDNA machine learning model","volume":"13","author":"Wu","year":"2024","journal-title":"Cancer Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","article-title":"Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition","volume":"183","author":"Nabet","year":"2020","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1186\/s12885-025-14583-1","article-title":"Cerebrospinal fluid circulating tumor DNA (ctDNA) as a biomarker for CNS metastases in non-small cell lung cancer (NSCLC): A systematic review and meta-analysis comparing CSF ctDNA and traditional methods","volume":"25","author":"Olayode","year":"2025","journal-title":"BMC Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2023.2275150","article-title":"Circulating tumor DNA (ctDNA): Can it be used as a pan-cancer early detection test","volume":"61","author":"Duffy","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/jpm12010099","article-title":"Use of circulating tumour DNA (ctDNA) for measurement of therapy predictive biomarkers in patients with cancer","volume":"12","author":"Duffy","year":"2022","journal-title":"J Pers Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110066","article-title":"Circulating tumor DNA (ctDNA) application in investigation of cancer: Bench to bedside","volume":"758","author":"Alsaab","year":"2024","journal-title":"Arch Biochem Biophys"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1911583\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:39:48Z","timestamp":1787225988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1911583\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2026.1911583"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1911583","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1911583"}}